N115 Nasal Spray Found to Improve Lung Function in PF Patients

N115 Nasal Spray Found to Improve Lung Function in PF Patients

308705

N115 Nasal Spray Found to Improve Lung Function in PF Patients

Treatment with N115, EmphyCorp’s non-steroidal nasal spray, led to statistically and clinically significant improvements across all lung function parameters in patients with pulmonary fibrosis (PF) participating in a Phase 3 trial, data show. Now, data from two other Phase 3 clinical trials suggest that N115 also may be beneficial for people infected with SARS-CoV-2, the virus that causes COVID-19, including “long haulers” — patients who continue experiencing symptoms of the disease long after testing negative. Long-term…

You must be logged in to read/download the full post.